TrialSuprachoroidal Administration in Subjects With Metastases to the Choroid
Trial details
- Registry ID
- NCT06643884
- Phase
- Phase 2
Drug research
AU-011
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Suprachoroidal Administration in Subjects With Metastases to the ChoroidNCT06643884 | Aura Biosciences | Phase 2 | Recruiting | 2026-11-30Estimated |
| Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaNCT04417530 | Aura Biosciences | Phase 2 | Completed | 2024-04-22Actual |
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Trial details
- Registry ID
- NCT04417530
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |